Resources

COVID-19 is sparking new demands on Ontario health system leaders – and the surge of need is bigger than traditional communications can carry. There is risk in duplication and gaps in expertise. REAL Resources is our way of curating the disparate information sources reviewed in the development of REAL Notes, and those submitted by others adding to our body of knowledge.

REAL Resources is a common ground for decision makers to find what is working and to see how it works in practice.

Filters

Resource Types
Resource Title Details Published
Ascending Descending

Australian guidelines for clinical care of people with COVID-19 — National COVID-19 Clinical Evidence Taskforce

Type:

Tags: , ,

October 27, 2020

Treatment for COVID-19 — Harvard Medical School

Type:

Tags: , ,

October 22, 2020

Remdesivir — CADTH: Canadian Agency for Drugs and Technologies in Health

Type:

Tags: , ,

October 21, 2020

Drugs and vaccines for COVID-19: List of authorized clinical trials — Government of Canada

Type:

Tags: , ,

October 20, 2020

“Solidarity” clinical trial for COVID-19 treatments — WHO: World Health Organization

Type:

Tags: , ,

October 14, 2020

Therapeutic Management of Patients with COVID-19 — National Institutes of Health

Type:

Tags: , ,

October 8, 2020

The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19 — Harbuwono et al.

Type:

Tags: , , ,

September 21, 2020

Treatments — BCCDC: British Columbia Centre for Disease Control

Type:

Tags: , ,

September 20, 2020

Favipiravir, Protease Inhibitors, Oseltamivir -Gpo, Hydroxychloroquine for Treatment of COVID-19 (FIGHT-COVID-19) — Kongsaengdao et al.

Type:

Tags: , , ,

August 31, 2020

More about chloroquine and hydroxychloroquine — CEBM: The Centre for Evidence-Based Medicine

Type:

Tags: , ,

August 29, 2020